These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6648 related articles for article (PubMed ID: 2451881)

  • 1. Curative combination chemotherapy for patients with advanced poorly differentiated carcinoma of unknown primary site.
    Hainsworth JD; Dial TW; Greco FA
    Am J Clin Oncol; 1988 Apr; 11(2):138-45. PubMed ID: 2451881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of cisplatin/bleomycin-based chemotherapy in the treatment of poorly differentiated carcinoma of unknown primary site.
    Hainsworth JD; Johnson DH; Greco FA
    Semin Oncol; 1992 Apr; 19(2 Suppl 5):54-7; discussion 58. PubMed ID: 1384145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.
    Hainsworth JD; Johnson DH; Greco FA
    J Clin Oncol; 1992 Jun; 10(6):912-22. PubMed ID: 1375284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etoposide/cisplatin-based chemotherapy for patients with metastatic poorly differentiated carcinoma of unknown primary site.
    Greco FA; Johnson DH; Hainsworth JD
    Semin Oncol; 1992 Dec; 19(6 Suppl 13):14-8. PubMed ID: 1492223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poorly differentiated carcinoma or adenocarcinoma of unknown primary site: long-term results with cisplatin-based chemotherapy.
    Greco FA; Hainsworth JD
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):77-82. PubMed ID: 7992071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of etoposide in the treatment of poorly differentiated carcinoma of unknown primary site.
    Hainsworth JD; Johnson DH; Greco FA
    Cancer; 1991 Jan; 67(1 Suppl):310-4. PubMed ID: 1984833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome.
    Greco FA; Vaughn WK; Hainsworth JD
    Ann Intern Med; 1986 Apr; 104(4):547-53. PubMed ID: 3006571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carcinoma of unknown primary: identification of a treatable subset?
    van der Gaast A; Verweij J; Henzen-Logmans SC; Rodenburg CJ; Stoter G
    Ann Oncol; 1990; 1(2):119-22. PubMed ID: 1706613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The management of patients with adenocarcinoma and poorly differentiated carcinoma of unknown primary site.
    Greco FA; Hainsworth JD
    Semin Oncol; 1989 Aug; 16(4 Suppl 6):116-22. PubMed ID: 2669133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taxane-based chemotherapy for patients with carcinoma of unknown primary site.
    Greco FA; Gray J; Burris HA; Erland JB; Morrissey LH; Hainsworth JD
    Cancer J; 2001; 7(3):203-12. PubMed ID: 11419028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study.
    Saghatchian M; Fizazi K; Borel C; Ducreux M; Ruffié P; Le Chevalier T; Théodore C
    Ann Oncol; 2001 Apr; 12(4):535-40. PubMed ID: 11398889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site.
    van der Gaast A; Verweij J; Planting AS; Hop WC; Stoter G
    J Clin Oncol; 1995 Jul; 13(7):1720-5. PubMed ID: 7541451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site.
    Motzer RJ; Rodriguez E; Reuter VE; Bosl GJ; Mazumdar M; Chaganti RS
    J Clin Oncol; 1995 Jan; 13(1):274-82. PubMed ID: 7799031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity.
    Hainsworth JD; Johnson DH; Greco FA
    Ann Intern Med; 1988 Sep; 109(5):364-71. PubMed ID: 2841895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poorly differentiated carcinoma of unknown primary site: correlation of light microscopic findings with response to cisplatin-based combination chemotherapy.
    Hainsworth JD; Wright EP; Gray GF; Greco FA
    J Clin Oncol; 1987 Aug; 5(8):1275-80. PubMed ID: 2442318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site.
    Greco FA; Hainsworth JD
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-101-S19-105. PubMed ID: 9427278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site.
    Karapetis CS; Yip D; Virik K; Strickland A; Ryder K; Cowling M; Harper PG
    Med Oncol; 2001; 18(1):23-32. PubMed ID: 11778966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poorly differentiated carcinoma of unknown primary site: clinical usefulness of immunoperoxidase staining.
    Hainsworth JD; Wright EP; Johnson DH; Davis BW; Greco FA
    J Clin Oncol; 1991 Nov; 9(11):1931-8. PubMed ID: 1941051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
    Hainsworth JD; Erland JB; Kalman LA; Schreeder MT; Greco FA
    J Clin Oncol; 1997 Jun; 15(6):2385-93. PubMed ID: 9196154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of patients with cancer of unknown primary site.
    Hainsworth JD; Greco FA
    Oncology (Williston Park); 2000 Apr; 14(4):563-74; discussion 574-6, 578-9. PubMed ID: 10826316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 333.